Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gamma-secretase inhibition.

D Beher1, M S Shearman

  • 1Department of Biochemistry and Molecular Biology, Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Harlow, Essex CM20 2QR, UK. dirk_beher@merck.com

Biochemical Society Transactions
|August 28, 2002
PubMed
Summary

Alzheimer's disease pathology is linked to amyloid-beta peptide (A beta) metabolism. Inhibiting gamma-secretase, which generates A beta, is a therapeutic target, but its effects on other substrates like Notch must be carefully evaluated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia.

Neuropathology and applied neurobiology·2006
Same author

Two domains within the first putative transmembrane domain of presenilin 1 differentially influence presenilinase and gamma-secretase activity.

Journal of neurochemistry·2005
Same author

Determination of guinea-pig cortical gamma-secretase activity ex vivo following the systemic administration of a gamma-secretase inhibitor.

Neuropharmacology·2005
Same author

Subcellular targeting of DISC1 is dependent on a domain independent from the Nudel binding site.

Molecular and cellular neurosciences·2005
Same author

Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders.

Molecular and cellular neurosciences·2004
Same author

The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.

European journal of biochemistry·2001

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Alzheimer's disease (AD) pathology is associated with age-dependent alterations in amyloid-beta peptide (A beta) metabolism, promoting aggregation and deposition.
  • Gamma-secretase is a key enzyme in A beta generation from the amyloid-beta precursor protein, making it a significant therapeutic target for AD.
  • Presenilin expression influences gamma-secretase activity, and studies confirm presenilins may form part of the enzyme's catalytic site.

Purpose of the Study:

  • To explore gamma-secretase as a therapeutic target for Alzheimer's disease.
  • To investigate the development and application of gamma-secretase inhibitors.
  • To assess the impact of gamma-secretase inhibition on other cellular processes and therapeutic safety.

Main Methods:

Related Experiment Videos

  • Identification of gamma-secretase inhibitors with transition-state analogue mimics.
  • Utilizing mutagenesis and knockout studies to confirm presenilin's role in the catalytic site.
  • Conducting proof-of-concept studies in animals and humans to determine optimal inhibition levels.

Main Results:

  • Compounds that specifically reduce gamma-secretase activity are being developed and tested.
  • Ongoing studies aim to define the necessary extent and duration of gamma-secretase inhibition for therapeutic benefit.
  • Gamma-secretase-mediated cleavage is identified as regulated intramembrane proteolysis.

Conclusions:

  • Gamma-secretase inhibitors show promise for Alzheimer's disease treatment.
  • Careful evaluation of gamma-secretase inhibitor effects on other substrates, such as Notch signaling, is crucial.
  • Understanding off-target effects is essential for determining safe and effective clinical dosing.